IDEX’s mission-critical precision components, HST technology exposure, and disciplined acquisitions support premium-quality compounding despite cyclical industrial risks.
Overview
IDEX Corporation is a decentralized, specialized industrial technology company with more than forty businesses across Health & Science Technologies, Fluid & Metering Technologies, and Fire & Safety / Diversified Products. It sells precision components and systems whose low cost relative to the operational, regulatory, or safety consequences of failure creates pricing power, design-in status, and multi-year customer lock-in. **Q2 2026 demonstrated accelerating momentum:** net sales reached a record $920.6 million, up 6% reported and 5% organically, while adjusted diluted EPS increased 12% to $2.32 and beat consensus by $0.22. Record orders of $1.0716 billion, up 29% reported and 28% organically, support the outlook, particularly in HST. Management raised FY 2026 organic sales growth guidance to 5%–6%, adjusted EBITDA margin guidance to 27.0%–27.3%, and adjusted diluted EPS guidance to $8.70–$8.85. The company trades at approximately 25.1x forward P/E and 18x forward EV/EBITDA, a premium justified by high margins, mission-critical products, low capital intensity, and free cash flow conversion of at least 100% of net income. The principal catalysts are HST organic growth, Mott integration, and stabilization of short-cycle industrial orders; the principal risks are semiconductor cyclicality, dual sourcing, and acquisition execution.